Focused On-demand Library for Synaptonemal complex central element protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8N0S2

UPID:

SYCE1_HUMAN

Alternative names:

Cancer/testis antigen 76

Alternative UPACC:

Q8N0S2; B2RC80; Q9BWU3; Q9BWU4

Background:

Synaptonemal complex central element protein 1, also known as Cancer/testis antigen 76, plays a pivotal role in meiosis, a process critical for sexual reproduction. It is a major component of the transverse central element of synaptonemal complexes (SCS), which form between homologous chromosomes during meiotic prophase. Its presence is essential for the incorporation into the central element, suggesting a significant role in synaptonemal complex assembly, stabilization, and recombination.

Therapeutic significance:

The protein's involvement in Premature ovarian failure 12 and Spermatogenic failure, 15, conditions affecting fertility, underscores its potential as a target for therapeutic intervention. Understanding the role of Synaptonemal complex central element protein 1 could open doors to potential therapeutic strategies for these reproductive disorders.